Lyell Immunopharma Files Definitive Proxy Statement
Ticker: LYEL · Form: DEF 14A · Filed: Apr 21, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | DEF 14A |
| Filed Date | Apr 21, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, annual-meeting
TL;DR
Lyell Immunopharma proxy filed, shareholders vote on directors & pay May 15.
AI Summary
Lyell Immunopharma, Inc. filed its definitive proxy statement on April 21, 2025, for its annual meeting on May 15, 2025. The filing outlines the company's governance and proposals to be voted on by shareholders, including the election of directors and executive compensation.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership and compensation, enabling informed voting decisions at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing, not indicating new financial or operational risks.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- 0001140361-25-014721 (filing_id) — Accession Number
- 20250421 (date) — Filing Date
- 20250515 (date) — Meeting Date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information for the annual meeting, including proposals to be voted on, such as the election of directors and executive compensation.
When is the annual meeting of Lyell Immunopharma, Inc. scheduled?
The annual meeting of Lyell Immunopharma, Inc. is scheduled for May 15, 2025.
What is the filing date of this definitive proxy statement?
The definitive proxy statement was filed on April 21, 2025.
What is the Central Index Key (CIK) for Lyell Immunopharma, Inc.?
The Central Index Key (CIK) for Lyell Immunopharma, Inc. is 0001806952.
Where is Lyell Immunopharma, Inc. headquartered?
Lyell Immunopharma, Inc. is headquartered at 201 Haskins Way, South San Francisco, CA 94080.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 21, 2025 regarding Lyell Immunopharma, Inc. (LYEL).